[SCHEDULE 13G] Cyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock SEC Filing

Rhea-AI Filing Summary

Cyclacel Pharmaceuticals, Inc. Schedule 13G filed by Yap Kim Choy discloses beneficial ownership of 218,000 shares, representing 9.8% of the class. The filing states these shares are held with sole voting and dispositive power and that they were not acquired to change or influence control of the issuer. The statement identifies the filing as a Schedule 13G disclosure and includes a signature certifying the accuracy of the information.

Positive

• Beneficial ownership disclosed: 218,000 shares representing 9.8% of the class
• Sole voting and dispositive power: filer reports exclusive control over voting and disposition of the shares
• Certification of passive intent: filer states holdings were not acquired to change or influence control

Negative

• None.

Insights

Financial Analyst

TL;DR: A non-U.S. individual reports a near-10% stake, a material disclosure but not an active control claim.

The filing shows 218,000 shares (9.8%) held with sole voting and dispositive power by Yap Kim Choy. As a Schedule 13G, the filer indicates a passive intent by certifying the securities were not acquired to change or influence control. For investors, a stake approaching 10% is notable because it can attract attention from other shareholders and the market, but the filer explicitly disclaims control intent, which keeps this disclosure in the passive category.

Corporate Governance Expert

TL;DR: Disclosure is timely and complete for a passive investor owning a significant stake under Schedule 13G.

The statement records sole voting and dispositive authority over the disclosed shares and includes the required certification that the holdings are not intended to influence control. From a governance perspective, the filer’s classification and certification align with passive investor reporting obligations, but the near-10% holding could warrant monitoring for any future changes in intent or filings that would convert the position to an active role.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Cyclacel Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

23254L876

(CUSIP Number)

07/28/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 23254L876

1

Names of Reporting Persons

Yap Kim Choy

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MALAYSIA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 218,000.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 218,000.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

218,000.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.8 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Cyclacel Pharmaceuticals, Inc.
(b)	Address of issuer's principal executive offices: Level 10, Tower 11, Avenue 5, No. 8 Jalan Kerinchi, Kuala Lumpur, Malaysia
Item 2.
(a)	Name of person filing: Yap Kim Choy
(b)	Address or principal business office or, if none, residence: 18-25-3A THE WHARF RESIDENCE TAMAN PUCHONG PRIMA PUCHONG 47200 SELANGOR MALAYSIA
(c)	Citizenship: Malaysia
(d)	Title of class of securities: Common Stock, par value $0.001 per share
(e)	CUSIP No.: 23254L876
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 218,000
(b)	Percent of class: 9.8%
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 218,000
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 218,000
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Yap Kim Choy

Signature:	/s/ Yap Kim Choy
Name/Title:	Yap Kim Choy
Date:	08/18/2025

Exhibit Information

sec.gov/Archives/edgar/data/1130166/000164117225015874/ex10-1.htm

FAQ

How many Cyclacel Pharmaceuticals (CYCCP) shares does Yap Kim Choy report owning?

The filing reports 218,000 shares beneficially owned.

What percentage of the class does the reported holding represent for CYCCP?

The reported holding represents 9.8% of the class.

Does the Schedule 13G state whether the shares were acquired to influence control of the issuer?

Yes. The filer certifies the securities were not acquired and are not held to change or influence control of the issuer.

What voting and dispositive powers are reported for the CYCCP shares?

The filer reports sole voting power and sole dispositive power over the 218,000 shares; no shared powers are reported.

When was the Schedule 13G signed?

The signature date on the filing is 08/18/2025.